Study wrapper · #1097
Tirzepatide in recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes: a case report.
Lechner B, Lechner K, Freibothe I, et al. Cardiovascular diabetology. Endocrinology reports. 2026.
DOI: 10.1186/s40842-026-00318-zPubMed: 42538551
Editor's note
This case report explores tirzepatide's use in a setting where incretin therapy is often withheld, describing a favorable course that the authors explicitly frame as association rather than causation. As a single-patient observation it is hypothesis-generating and should be read in that light.
Plain-language abstract
This single case describes a woman with recurrent hypertriglyceridemia-mediated pancreatitis and type 2 diabetes whose triglycerides normalized and pancreatitis episodes stopped after tirzepatide was started. The authors emphasize this is an association only and does not establish causality.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Weak / none
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.
Obesity pillarsn=——2026